Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
AACR 2025 preview – distressed biotechs seek redemption
Ikena, Senti and others look to clinical presentations at AACR.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
